Related conditions

Primary Orbital Plasmacytoma Mimicking Lacrimal Gland Tumor. Bhadauria M et al. Orbit. 2014 May 15:1-3. [Epub ahead of print]. Atypical blast morphology of primary plasma cell leukemia with renal involvement and plasmablasts in urine. Pavlovic A et al. Diagn Cytopathol. 2014 May 15. doi: 10.1002/dc.23168. [Epub ahead of print]. Amyloidosis in bilateral external auditory canals.…

Emerging treatments

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Harvey RD. Clin Pharmacol. 2014 May 8;6:87-96. eCollection 2014. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Bringhen S et al. Blood. 2014 May 22. pii: blood-2014-03-563759. [Epub ahead of…

General

Updates to the guidelines for the diagnosis and management of multiple myeloma. Pratt G et al. Br J Haematol. 2014 May 7. doi: 10.1111/bjh.12926. [Epub ahead of print]. Multiple myeloma: advances reported in 2013 are useful in the clinic. Anderson K. J Natl Compr Canc Netw. 2014 May;12(5 Suppl):808-11. Role of new drugs incorporated into…

Supportive care

Clinical benefits of femoroplasty: a nonsurgical alternative for the management of femoral metastases. Plancarte R et al. Pain Physician. 2014 May-Jun;17(3):227-34. Comparative Effectiveness on Survival of Zoledronic Acid versus Pamidronate in Multiple Myeloma. Sanfilippo K et al. Leuk Lymphoma. 2014 May 21:1-22. [Epub ahead of print]. Aprepitant for the control of delayed nausea and vomiting…

Complications of myeloma and its treatments

Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Greenfield DM et al. Bone Marrow Transplant. 2014 May 19. doi: 10.1038/bmt.2014.103. [Epub ahead of print]. Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture: a clinical perspective. Bours…

Current treatments

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Leiba M et al. Br J Haematol. 2014 May 26. doi: 10.1111/bjh.12946. [Epub ahead of print]. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for newly diagnosed myeloma multiple patients. Blanes M…

Related conditions

Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Vrana JA et al. Haematologica. 2014 Apr 18. [Epub ahead of print]. A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia. Sorigue M et al. Cytometry B Clin Cytom. 2014 Apr 9. doi: 10.1002/cyto.b.21173. [Epub ahead of print]. A rare cause…

General

United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. Rabin N et al. Int J Lab Hematol. 2014 Mar 27. doi: 10.1111/ijlh.12205. [Epub ahead of print]. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow…